US6001386A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Implantable controlled release device to deliver drugs directly to an internal portion of the body
Assignee: University of Kentucky Research Foundation
•
Filing: 1998-04-14
•
Granted: 1999-12-14
•
Expires: 2018-04-14
Abstract
Abstract A simple and implantable sustained release drug delivery device with an inner core containing an effective amount of a low solubility agent covered by a non-bioerodible polymer coating layer that is permeable to the low solubility agent is disclosed. A method for treating a mammal to obtain a desired local or systemic physiological or pharmacological effect by surgically implanting such a sustained release drug delivery device into a mammal in need of treatment is also disclosed.
Inventors
- 👤 Paul Ashton
- 👤 Paul A. Pearson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 22:13
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051; A61F; A61F9/00; A61F9/0008; A61F9/0017; A61M; A61M31/00; A61M31/002; A61P; A61P27/00; A61P27/02
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
48 words
A sustained release drug delivery device comprising: an inner core comprising an effective amount of an agent having a solubility less than about 10 μgml; and a polymer coating layer, the polymer layer being permeable to the agent, wherein the polymer coating layer completely covers the inner core.
Claim 2
Dependent Claim
48 words
A sustained release drug delivery device comprising: an inner core comprising an effective amount of an agent having a solubility less than about 10 μgml; and a polymer coating layer, the polymer layer being permeable to the agent, wherein the polymer coating layer completely covers the inner core.
Claim 3
Dependent Claim
18 words
The device according to claim 1, wherein the solubility of the agent is about 0.01 μg/ml-about 0.001 μg/ml.
Claim 4
Dependent Claim
18 words
The device according to claim 1, wherein the solubility of the agent is about 0.001 μg/ml-about 0.0001 μg/ml.
Claim 5
Dependent Claim
18 words
The device according to claim 1, wherein the solubility of the agent is less than about 0.0001 μg/ml.
Claim 6
Dependent Claim
12 words
The device according to claim 1, wherein the agent has low solubility.
Claim 7
Dependent Claim
12 words
The device according to claim 1, wherein the agent is slightly soluble.
Claim 8
Dependent Claim
13 words
The device according to claim 1, wherein the agent is very slightly soluble.
Claim 9
Dependent Claim
14 words
The device according to claim 1, wherein the agent is practically insoluble or insoluble.
Claim 10
Independent Claim
77 words
A method for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect comprising: administering a sustained release drug delivery device to a mammalian organism in need of such treatment, the drug delivery device comprising: an inner core comprising an effective amount of a low solubility agent; and a polymer coating layer, the polymer layer being permeable to the low solubility agent, wherein the polymer coating layer completely covers the inner core.
Claim 11
Independent Claim
77 words
A method for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect comprising: administering a sustained release drug delivery device to a mammalian organism in need of such treatment, the drug delivery device comprising: an inner core comprising an effective amount of a low solubility agent; and a polymer coating layer, the polymer layer being permeable to the low solubility agent, wherein the polymer coating layer completely covers the inner core.
Claim 12
Dependent Claim
18 words
The method according to claim 9, wherein the solubility of the agent is about 0.01 μg/ml-about 0.001 μg/ml.
Claim 13
Dependent Claim
18 words
The method according to claim 9, wherein the solubility of the agent is about 0.001 μg/ml-about 0.0001 μg/ml.
Claim 14
Dependent Claim
18 words
The method according to claim 9, wherein the solubility of the agent is less than about 0.000 μg/ml.
Claim 15
Dependent Claim
12 words
The method according to claim 9, wherein the agent has low solubility.
Claim 16
Dependent Claim
12 words
The method according to claim 9, wherein the agent is slightly soluble.
Claim 17
Dependent Claim
13 words
The method according to claim 9, wherein the agent is very slightly soluble.
Claim 18
Dependent Claim
14 words
The method according to claim 9, wherein the agent is practically insoluble or insoluble.
Claim 19
Dependent Claim
41 words
A sustained release drug delivery device comprising: an inner core comprising an effective amount of fluocinolone acetonide; and a polymer coating layer, the polymer layer being permeable to the fluocinolone acetonide, wherein the polymer coating layer completely covers the inner core.
Claim 20
Dependent Claim
41 words
A sustained release drug delivery device comprising: an inner core comprising an effective amount of fluocinolone acetonide; and a polymer coating layer, the polymer layer being permeable to the fluocinolone acetonide, wherein the polymer coating layer completely covers the inner core.
Claim 21
Independent Claim
74 words
A method for treating a mammalian organism to obtain a desired local or systemic physiological of pharmacological effect comprising: administering a sustained release drug delivery device to a mammalian organism in need of such treatment, the drug delivery device comprising: an inner core comprising an effective amount of fluocinolone acetonide; and a polymer coating layer, the polymer layer being permeable to the fluocinolone acetonide, wherein the polymer coating layer completely covers the inner core.
Claim 22
Independent Claim
74 words
A method for treating a mammalian organism to obtain a desired local or systemic physiological of pharmacological effect comprising: administering a sustained release drug delivery device to a mammalian organism in need of such treatment, the drug delivery device comprising: an inner core comprising an effective amount of fluocinolone acetonide; and a polymer coating layer, the polymer layer being permeable to the fluocinolone acetonide, wherein the polymer coating layer completely covers the inner core.
References Cited (Backward Citations)
US5378475A
Cited
US5773019A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-12-13 | 2003-06-14 | 2003-12-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-12-13 | 2007-06-14 | 2007-12-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-12-13 | 2011-06-14 | 2011-12-14 | $7700.00 | Window Closed / Lapsed |